# An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

> **NCT02182206** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 50 (actual)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT02182206
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-06
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182206, "An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*